Why China drug firms for top? Into the line of low 
 
  
In the 2015-02-05 s but 
 
 
Source: flush
 
The original address: http://f.sdnews.com.cn/qyjj/201502/t20150205_1846063.htm 

    Bai Huiliang told reporters that does not include the production of traditional Chinese medicine yinpian enterprise, only in the field of pharmaceutical preparation in our country enterprise has more than 4500, but nine become small businesses.

    "China is pharmaceutical giants. The number of drug companies and API production scale is ahead in the world." Bai Huiliang said, but unfortunately, the Chinese medical field in the world are always no. This is because the Chinese drug companies are facing the current situation of "a little more than two three low.
 
    A small, small scale enterprises. Bai Huiliang told reporters that does not include the production of traditional Chinese medicine yinpian enterprise, only in the field of pharmaceutical preparation in our country enterprise has more than 4500, but nine become small businesses. In 2013 China top 500 enterprises, drug firms only 15; In 2010, sales revenue exceeds 10 billion yuan of drug firms only 10, 5 billion yuan only 17.
 
    2: generic drug production, products to repeat. First of all, ming-de yu pointed out that at present our country more than 90% of the domestic medicine for generic drugs. Cows are dry, explained that generics, it refers to the original drug in dosage, quality, safety and efficacy, and adapt to the crowd on the same or similar to a kind of imitation. Second, most drug firms in China famous brand product, less repetitive, blind expansion phenomenon is outstanding, such as clarithromycin, luo erythromycin, azithromycin and levofloxacin antibiotics, such as flood, drug companies often itself in a situation of oversupply.
 
    Three low: low innovation ability, low drug quality, market competitiveness is low. Bai Huiliang pointed out that the development of pharmaceutical companies in China most pharmaceutical technology content is low, concentrated in generic drugs, based on the disease of drug therapy, such as antitumor medicine high-end medicine basic didn't share, can only rely on imports, leading to low competitiveness. As generics companies produced, numerous companies on price, even at the expense of quality to reduce the cost, resulting in a decline in the quality. Bai Huiliang says many of the generic drugs even amounted to less than 60% of the original drug curative effect.
 
    why
 
    Low barriers to entry policy
 
    Chinese drug companies and foreign companies a huge gap from four aspects.
 
    First, China's pharmaceutical industry quality standard threshold is low, has resulted in thousands of companies engaged in generic drug production. And can meet the national standards of drug production quality management of the enterprise often have no incentive to impact the international standard, also can't enter the international market.
 
    Second, China's pharmaceutical industry affected by the policy. Drug prices, national development and reform commission (NDRC) since 1998, introduced in 2009 and began to implement "basic drug bidding system, drug prices, has been down for some small and medium-sized enterprises in the edge of life and death struggle. He Tianli pointed out: "health is a good thing, but always reform drug prices, inevitably lead to some enterprises to control costs, reduce the drug quality, vicious competition."
 
    Third, administrative examination and approval process is very troublesome. Ming-de yu said that new drug application for clinical record or ask for instructions before approval process will take about more than 20 months, and only more than 1 months to abroad. Please batch number, examination and approval of personnel less, sometimes it needs three or four years. Many medicine two to three years in healthcare, affect patients timely, also hit corporate r&d enthusiasm.
 
    Fourth, this TuYao enterprise support is not enough. He Tianli pointed out that since the reform and opening, the state attaches great importance to the introduction of foreign investment, foreign enterprises enjoy preferential policies, great impact on local companies. Automobile, energy and other domestic enterprises in China have support, protection, not only medicine. "Crack pharmaceutical early no policy support, in scientific research, the pricing is restricted, have to make some policy support by way of joint venture, is to live on the margins of society."
 
    countermeasures
 
    A leading drug companies have reward mechanism
 
    "To change the status quo of Chinese drug firms, should first to streamline drug firms team, develop leading pharmaceutical companies, to create good competition environment and development." A former working in drug firms of the personage inside course of study tells a reporter. In recent years, the world's top ten pharmaceutical companies, such as Pfizer, sanofi, Merck, novartis, began large-scale merger and reorganization, make the business diversification.
 
    In 2010 ~ 2015 is intensive period of new drug patents expire. Such as in November 2011, Pfizer's cholesterol-lowering drug lipitor patents expire, generic drugs are listed, make lipitor sales fell 24% in the fourth quarter. Analysts say, is expected to around 2015, domestic generics scale is likely to be close to 500 billion yuan, it's a good news for domestic pharmaceutical companies.
 
    To improve the international competitiveness of Chinese medicine enterprises is to promote research and development ability. State major drug discovery "special" plan proposed that our country developed 30 to 2015 original new drugs; By 2020 for new drug research and development capacity of the world first-class level. In recent years, a breakthrough in the innovation medicine in China, many enterprises taste, such as hainan crack pharmaceutical production of cold medicine with annual sales of 700 million yuan. Tasly group salvia miltiorrhiza dropping pill for ten consecutive years sales revenue exceeds 1 billion yuan. Ming-de yu pointed out that the advanced new drugs, the country should improve the speed of examination and approval, in the aspect of land, tax, platform building preferential treatment. New drugs into the health care is also very important, but the country can afford restricted the policy implementation. Experts suggest may be paid in proportion, such as ordinary drugs reimbursement 75%, new drug can submit an expense account 50% ~ 50%, even 30%. China association of enterprises with foreign investment in drug research and development industry commission, chief executive ZhuoYongQing innovation through incentives to motivate and encourage innovation through rapid market access and reasonable pricing. Innovative personnel training should be strengthened and the introduction of overseas talent strength, encourages industrial training.
 
    The gap between
 
    R&d spending less innovation ability is poor
 
    As the saying goes "as you sow, so shall you reap." Drug firms of China the status quo of "a little more than two three low" pulled open the distance of the top with the world. In 2010, the China association of enterprises with foreign investment in drug research and development industry committee in the pharmaceutical enterprise quality system research project report, released a set of data: in the Chinese mainland market, the American drug companies accounted for 64%; In the top ten domestic drug firms up of the total market share of less than 5%.
 
    The gap mainly embodies in new drug research and development capabilities. Development of new drugs is a high investment, high risk and high profit industry. Cows are dry, the production of innovative medicine for drug screening and animal experiments, and then the issue, phase ii, phase iii clinical trials, finally by the agency for approval and to the market. International cost has amounted to $500 million to $1 billion, new drug research and development period of more than 10 years. People often use "blockbuster" to describe the birth of new drugs, because it is not only a medical breakthrough, also can create up to 30% of the profits. Big global r&d costs generally up to 12% of sales, such as America's Pfizer production of sildenafil (viagra) in China's average annual sales of more than 500 million yuan, its research and development is also the world's highest.
 
    In contrast, our country in new drug research and development spending on trivial. "Only 2%, some enterprises doesn't even have 2%, some good companies can achieve 3% ~ 4%." Bai Huiliang said. "Pharmaceutical enterprise quality system research project", the report also shows that innovation medicine less than 30% in our country, and abroad has reached more than 50%. China in the field of biopharmaceuticals is far off, the more the United States, the European Union, international market share of more than 95% of biomedicine, and other countries, including China, less than 5%.
 
    New drug research and development level is low, it will cause a negative chain reaction. A the personage inside course of study tells a reporter, the domestic most drug firms can't invest money and time to develop a new drug, so focus on generic drugs. But due to the low profit, competition is intense, there may be 1000 enterprises in the production of the same kind of drugs. Blindly follow others, leading to a local drug firms difficult to have a resume. "Some business has always been at a loss, more than 80% real profit drug firms are joint venture or foreign investment, which is entirely a matter of expensive branded drugs make a profit." Even in our country is popular generics, far from the international leading level, couldn't even ranked into the top.